Image-Guided Drug Delivery Market Drivers Include Technological Advancements Rising Healthcare Investments and Awareness

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Image-Guided Drug Delivery Market Size, Share & Trends Analysis Report By Technology Type (Drug-Delivery Systems and Image-Guided Platforms), Application (Oncology, Neurology, and Others), End-use (Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes & Universities, and Contract Research Organizations (CROs)),-Market Outlook And Industry Analysis 2034"

Image-Guided Drug Delivery Market Size is valued at US$ 58.9 Mn in 2024 and is predicted to reach US$ 687.4 Mn by the year 2034 at an 28.1% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3211

Image-guided drug delivery (IGDD) is a new clinical strategy that combines targeted drug delivery with imaging modalities to optimize therapeutic efficacy, safety, and accuracy. Real-time imaging of organs and tissues is accomplished through the use of imaging techniques like computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), or ultrasound.

By doing this, doctors may better regulate and direct the delivery of therapeutic medicines to the illness site-such as a tumor or diseased organ-while minimizing exposure to healthy tissues. The image-guided drug delivery market is expanding quickly due to advancements in medical technology and rising demand for precision medicine.

Moreover, the increasing prevalence of neurological disorders and cancer is another significant reason driving the expansion of the image-guided drug delivery market. Additionally, advancements in MRI, CT, and PET technology have improved this drug administration method's efficacy and reliability.

List of Prominent Players in the Image-Guided Drug Delivery Market:
• ClearPoint Neuro, Inc.
• AiM Medical Robotics
• TriSalus Life Sciences
• RenovoRx Inc.
• Renishaw plc.
• Occam Design
• Infuseon Therapeutics Inc
• Neurochase
• GE HealthCare
• Koninklijke Philips N.V.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics:
Drivers-
The continuous evolution of imaging modalities such as MRI, CT, PET, and ultrasound, which today provide enhanced spatial resolution and real-time visualization of drug distribution, is among the driving factors of the image-guided drug delivery market growth. These advancements enhance the efficacy of therapy, reduce off-target effects, and enable more precise targeting of ill regions. IGDD systems are also needed as a result of the increased global demand for customized and less intrusive therapy, particularly in oncology and neurology.

The increasing application of theranostic and customized medicine strategies-where treatment administration and imaging diagnostics are brought together to personalize treatments to the specific profile of each patient-is another key driver for the market. In addition, the image-guided drug delivery is anticipated to evolve due to the growing incidence of chronic diseases such as cancer, Alzheimer's, and cardiovascular issues, which require efficient and new treatment methods.

Challenges:
There are a number of obstacles that could prevent the image-guided drug delivery market from expanding. The high expense of MRI, CT, PET equipment, and associated infrastructure is one of the main obstacles. Widespread adoption is hampered by this, particularly in developing nations where there is a growing need for cutting-edge medical technology but ongoing financial limitations.

Furthermore, a major obstacle may be the intricacy of combining these technologies with drug delivery systems. The procedure calls for flawless synchronization between imaging and delivery equipment in addition to extremely precise drug administration. Due to the technical difficulties in accomplishing such integration, market penetration may be constrained by large initial investment prices.

Regional Trends:
In 2024, North America dominated the global image-guided drug delivery market due to a strong healthcare system, cutting-edge research and development (R&D) initiatives, and a large number of well-known medical device manufacturers. The area gains from large investments in cutting-edge technology like robotics, augmented reality, and artificial intelligence (AI), which have greatly improved the accuracy, effectiveness, and results of image-guided treatments.

In addition, there are more and more senior persons in the United States who are afflicted with chronic illnesses like cancer, heart disease, and musculoskeletal disorders. Thus, this promotes the use of image-guided drug delivery in the United States.

Moreover, the expansion of healthcare infrastructure, rising investment in medical imaging technology, and increasing awareness of advanced treatment options are all supporting the quick expansion of the Asia Pacific image-guided drug delivery market. Due to their large patient populations and government initiatives to promote precision and minimally invasive treatments, countries such as China, Japan, South Korea, and India are experiencing remarkable growth.

The demand for effective and directed treatment methods is being driven by the increasing prevalence of neurological diseases and cancer within the region. In addition, collaborations between local healthcare providers and global medical technology firms are rendering access to advanced image-guided devices cheaper and more accessible.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3211

Recent Developments:
• August 2025: A significant milestone in clinical implementation was reached when ClearPoint Neuro, Inc. announced the first-ever commercial delivery of KEBILIDI (AADC deficient gene therapy) in the United States utilizing its FDA-approved SmartFlow Neuro Cannula.
• April 2025: Johns Hopkins Medicine began accepting patients with locally advanced pancreatic cancer (LAPC) into RenovoRx's TIGeR-PaC study. By contrasting it with conventional intravenous chemotherapy, the trial assesses RenovoRx's intra-arterial gemcitabine (IAG) delivery using the RenovoCath device. The trial is strengthened by this addition, which aims to reach complete enrollment by the end 2025.
• October 2023: The U.S. FDA has granted 510(k) approval to GE HealthCare's Allia IGS Pulse system. The system supported complex cardiac operations on patients of various sizes thanks to a newly built imaging chain that provided high-quality imaging at optimal radiation doses. The company's interventional portfolio is strengthened by this approval, which also helps to solidify its place in the market.

Segmentation of Image-Guided Drug Delivery Market-
By Technology Type-
• Drug-Delivery Systems
• Image-Guided Platforms
By Application-
• Oncology
• Neurology
• Others
By End-use-
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Research Institutes & Universities
• Contract Research Organizations (CROs)
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/image-guided-drug-delivery-market/3211

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.